HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Zohlnhöfer, D. Articles by Schömig, A. Search for Related Content PubMed PubMed Citation Articles by Zohlnhöfer, D. Articles by Schömig, A.

A Randomized, Double-Blind, Placebo-Controlled Trial on Restenosis Prevention by the Receptor Tyrosine Kinase Inhibitor Imatinib

Dietlind Zohlnhöfer, MD^_*,_*, Jörg Hausleiter, MD^_*, Adnan Kastrati, MD^_*, Julinda Mehilli, MD^_*, Christoph Goos^_*, Helmut Schühlen, MD^_*, Jürgen Pache, MD^_*, Gisela Pogatsa-Murray, MD^_*, Uwe Heemann, MD, Josef Dirschinger, MD and Albert Schömig, MD^_*

^_* Deutsches Herzzentrum München, Munich, Germany; Klinik an der Technische Universität München, Munich, Germany
2.Medizinische Klinik des Klinikum rechts der Isar, Technische Universität, Munich, Germany
1.Medizinische Klinik des Klinikums rechts der Isar, Technische Universität, Munich, Germany

View larger version (12K): [in a new window]   Figure 1 Bar graph demonstrating angiographic restenosis rates at six months and clinical restenosis rates at one year (need for target lesion revascularization [TLR], repeat coronary intervention, or bypass surgery). White bars = placebo; black bars = imatinib.

View larger version (16K): [in a new window]   Figure 2 Percent diameter stenosis in treatment groups.